{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:29:20Z","timestamp":1782926960977,"version":"3.54.5"},"reference-count":55,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Background: In the paediatric intensive care unit (PICU), certain drugs should be avoided or administered with strict precautions and close monitoring. This is due to their potential for toxicity or adverse effects or a lack of safety data, especially for critically ill children with organ failure. Additionally, practitioners must assess the unique pharmacokinetic and pharmacodynamic properties of drugs when treating critically ill children. In this narrative review, we highlight the risks, advantages, and disadvantages of three exemplary cases of drugs for paediatric patients hospitalised in the PICU: chloramphenicol, acetylsalicylic acid, and propofol. Methods: Apart from key papers on these drugs, a retrospective analysis of the English literature on chloramphenicol, acetylsalicylic acid (ASA), and propofol was performed on PubMed for papers from January 2014 to December 2025. Results: Chloramphenicol should be avoided in neonates due to the risk of grey baby syndrome. Acetylsalicylic acid (ASA) is contraindicated in children \u226418 years with suspected viral illness because of the risk of Reye\u2019s syndrome, but remains essential for Kawasaki disease and post-cardiac surgery antiplatelet therapy. Propofol should be avoided when used for a longer period at high doses. With proper dosing and monitoring, propofol-related infusion syndrome (PRIS) is preventable, but high-risk patients should receive alternative treatment. Conclusions: This narrative review highlights the significant risks associated with the use of chloramphenicol, ASA, and propofol in paediatric intensive care settings. Their potential for life-threatening and severe adverse reactions emphasises the need for cautious and informed use. Clinicians must carefully consider the risks and benefits of these drugs. To minimise adverse events, strict monitoring, dose adjustments, and the use of safer alternatives are essential. However, it appears that their use in well-defined circumstances in acute illness in children is still warranted. The findings of this narrative review underscore the need for further research to focus on identifying high-risk biomarkers, genetic predispositions, and safer alternatives to improve evidence-based guidelines and reduce morbidity and mortality in paediatric intensive care.<\/jats:p>","DOI":"10.3390\/children13040579","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:01:24Z","timestamp":1776848484000},"page":"579","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Potentially Hazardous Drugs in the Paediatric ICU: A Narrative Review on the Exemplary Cases of Propofol, Chloramphenicol, and Acetylsalicylic Acid"],"prefix":"10.3390","volume":"13","author":[{"given":"Laura","family":"Beckers","sequence":"first","affiliation":[{"name":"Anaesthesiology, Antwerp University Hospital, 2650 Edegem, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joery","family":"Verbruggen","sequence":"additional","affiliation":[{"name":"(Paediatric) Critical Care Medicine, Antwerp University Hospital, 2650 Edegem, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Saldien","sequence":"additional","affiliation":[{"name":"Anaesthesiology, Antwerp University Hospital, 2650 Edegem, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozef","family":"De Dooy","sequence":"additional","affiliation":[{"name":"(Paediatric) Critical Care Medicine, Antwerp University Hospital, 2650 Edegem, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3870-6363","authenticated-orcid":false,"given":"Eva","family":"van Zanten","sequence":"additional","affiliation":[{"name":"(Paediatric) Critical Care Medicine, Antwerp University Hospital, 2650 Edegem, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-8127","authenticated-orcid":false,"given":"Thomas","family":"Peros","sequence":"additional","affiliation":[{"name":"(Paediatric) Critical Care Medicine, Antwerp University Hospital, 2650 Edegem, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Wiggelinkhuizen","sequence":"additional","affiliation":[{"name":"(Paediatric) Critical Care Medicine, Antwerp University Hospital, 2650 Edegem, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-957X","authenticated-orcid":false,"given":"Philippe G.","family":"Jorens","sequence":"additional","affiliation":[{"name":"(Paediatric) Critical Care Medicine, Antwerp University Hospital, 2650 Edegem, Antwerp, Belgium"},{"name":"LEMP Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"ref_1","first-page":"422","article-title":"Pediatric pharmacy association 2025 KIDs list of key potentially inappropriate drugs in pediatrics","volume":"30","author":"McPherson","year":"2025","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_2","first-page":"175","article-title":"Key potentially inappropriate drugs in pediatrics: The KIDs list","volume":"25","author":"Meyers","year":"2020","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12995-016-0118-5","article-title":"Acetylsalicylic acid as a potential pediatric health hazard: Legislative aspects concerning accidental intoxications in the European Union","volume":"11","author":"Mund","year":"2016","journal-title":"J. Occup. Med. Toxicol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.anclin.2017.01.012","article-title":"Pharmacologic considerations of anesthetic agents in pediatric patients: A comprehensive review","volume":"35","author":"Kaye","year":"2017","journal-title":"Anesthesiol. Clin."},{"key":"ref_5","first-page":"S10","article-title":"Developmental changes in pharmacokinetics and pharmacodynamics","volume":"58","author":"Reed","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_6","first-page":"S141","article-title":"Considerations for drug dosing in premature infants","volume":"61","author":"Allegaert","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.ejps.2017.05.023","article-title":"Non-maturational covariates for dynamic systems pharmacology models in neonates, infants, and children: Filling the gaps beyond developmental pharmacology","volume":"109S","author":"Allegaert","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.4065\/74.8.825","article-title":"Clindamycin, metronidazole, and chloramphenicol","volume":"74","author":"Kasten","year":"1999","journal-title":"Mayo Clin. Proc."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/BF00788231","article-title":"Chloramphenicol toxicity associated with severe cardiac dysfunction","volume":"13","author":"Suarez","year":"1992","journal-title":"Pediatr. Cardiol."},{"key":"ref_10","first-page":"675","article-title":"The impact of pharmacogenetics on pharmacokinetics and pharmacodynamics in neonates and infants: A systematic review","volume":"15","author":"Flint","year":"2022","journal-title":"Pharmacogenomics Pers. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/jphp.12630","article-title":"Pharmacological sedation management in the paediatric intensive care unit","volume":"69","author":"Baarslag","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1460-9592.2011.03548.x","article-title":"Exploring the pharmacokinetics of oral ketamine in children undergoing burns procedures","volume":"21","author":"Brunette","year":"2011","journal-title":"Paediatr. Anaesth."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/clinids\/3.3.479","article-title":"Chloramphenicol: A review of its use in clinical practice","volume":"3","author":"Feder","year":"1981","journal-title":"Rev. Infect. Dis."},{"key":"ref_14","unstructured":"Cummings, E.D., Kong, E.L., and Edens, M.A. (2024, June 11). Gray Baby Syndrome. StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK448133\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/clpt.1981.174","article-title":"Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate","volume":"30","author":"Nahata","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0022-3476(81)80670-1","article-title":"Pharmacokinetics of chloramphenicol and chloramphenicol succinate in infants and children","volume":"98","author":"Kauffman","year":"1981","journal-title":"J. Pediatr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.7326\/0003-4819-33-6-1459","article-title":"A fatal case of aplastic anemia following chloramphenicol (chloromycetin) therapy","volume":"33","author":"Rich","year":"1950","journal-title":"Ann. Intern. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jama.1950.02910350003002","article-title":"Hemopoietic changes during administration of chloramphenicol (chloromycetin)","volume":"142","author":"Volini","year":"1950","journal-title":"J. Am. Med. Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1136\/bmj.287.6403.1424","article-title":"Chloramphenicol toxicity in neonates: Its incidence and prevention","volume":"287","author":"Mulhall","year":"1983","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/000992288202100910","article-title":"Gray baby syndrome revisited","volume":"21","author":"Krasinski","year":"1982","journal-title":"Clin. Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/jac\/dku530","article-title":"Efficacy and safety of chloramphenicol: Joining the revival of old antibiotics? Systematic review and meta-analysis of randomized controlled trials","volume":"70","author":"Lador","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","unstructured":"Chapman, J., and Arnold, J.K. (2024, August 09). Reye Syndrome. StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526101\/."},{"key":"ref_23","first-page":"110","article-title":"Reye (Ray\u2019s) syndrome: A problem everyone should remember","volume":"272","author":"Chornomydz","year":"2017","journal-title":"Georgian Med. News"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1001\/jama.1989.03420170061031","article-title":"New epidemiologic evidence confirming that bias does not explain the aspirin\/Reye\u2019s syndrome association","volume":"261","author":"Forsyth","year":"1989","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1001\/jama.1987.03390140075030","article-title":"Public health service study of Reye\u2019s syndrome and medications. Report of the main study","volume":"257","author":"Hurwitz","year":"1987","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1056\/NEJM198510033131403","article-title":"Public health service study on Reye\u2019s syndrome and medications. Report of the pilot phase","volume":"313","author":"Hurwitz","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/adc.63.7.857","article-title":"Preadmission antipyretics in Reye\u2019s syndrome","volume":"63","author":"Hall","year":"1988","journal-title":"Arch. Dis. Child."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e932864","DOI":"10.12659\/AJCR.932864","article-title":"Reye syndrome with severe hyperammonemia and a good neurological outcome","volume":"22","author":"Pribozic","year":"2021","journal-title":"Am. J. Case Rep."},{"key":"ref_29","first-page":"34","article-title":"Reye syndrome: A case report with review of literature","volume":"47","author":"Ghosh","year":"2008","journal-title":"JNMA J. Nepal. Med. Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1056\/NEJM199905063401801","article-title":"Reye\u2019s syndrome in the united states from 1981 through 1997","volume":"340","author":"Belay","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1469-0691.2010.03196.x","article-title":"Fatal case of Reye\u2019s syndrome associated with h3n2 influenza virus infection and salicylate intake in a 12-year-old patient","volume":"17","author":"Ninove","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","first-page":"138","article-title":"Reye\u2019s syndrome","volume":"1","author":"Bajracharya","year":"2003","journal-title":"Kathmandu Univ. Med. J. (KUMJ)"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2165\/00002018-200629120-00003","article-title":"Reye\u2019s syndrome: The case for a causal link with aspirin","volume":"29","author":"Glasgow","year":"2006","journal-title":"Drug Saf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.pediatrneurol.2008.06.003","article-title":"Reye syndrome and Reye-like syndrome","volume":"39","author":"Gosalakkal","year":"2008","journal-title":"Pediatr. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/157488609787354378","article-title":"Reye\u2019s syndrome, encephalopathy, hyperammonemia and acetyl salicylic acid ingestion in a city hospital of Buenos Aires, Argentina","volume":"4","author":"Lemberg","year":"2009","journal-title":"Curr. Drug Saf."},{"key":"ref_36","first-page":"e2021110","article-title":"Atypical Reye syndrome: Three cases of a problem that pediatricians should consider and remember","volume":"92","author":"Ferretti","year":"2021","journal-title":"Acta Biomed."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1136\/adc.61.7.647","article-title":"Recognition and early management of Reye\u2019s syndrome","volume":"61","author":"Dezateux","year":"1986","journal-title":"Arch. Dis. Child."},{"key":"ref_38","first-page":"244","article-title":"Kawasaki disease and multisystem inflammatory syndrome in children: An overview and comparison","volume":"104","author":"Darby","year":"2021","journal-title":"Am. Fam. Physician"},{"key":"ref_39","first-page":"11786337211026642","article-title":"Multisystem inflammatory syndrome in children and adolescents (mis-c) under the setting of COVID-19: A review of clinical presentation, workup and management","volume":"14","author":"Farooq","year":"2021","journal-title":"Infect. Dis."},{"key":"ref_40","first-page":"788","article-title":"New insights in the pathogenesis and therapy of idiopathic recurrent pericarditis in children","volume":"31","author":"Gaspari","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_41","first-page":"e30383","article-title":"Propofol-related infusion syndrome: A clinical review","volume":"14","author":"Singh","year":"2022","journal-title":"Cureus"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.amjcard.2009.05.065","article-title":"Propofol infusion syndrome with arrhythmia, myocardial fat accumulation and cardiac failure","volume":"104","author":"Jorens","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1046\/j.1460-9592.1998.00282.x","article-title":"Propofol infusion syndrome in children","volume":"8","author":"Bray","year":"1998","journal-title":"Pediatr. Anesth."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.bja.2018.12.025","article-title":"Propofol infusion syndrome: A structured literature review and analysis of published case reports","volume":"122","author":"Hemphill","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00134-003-1905-x","article-title":"The pathophysiology of propofol infusion syndrome: A simple name for a complex syndrome","volume":"29","author":"Vasile","year":"2003","journal-title":"Intensive Care Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2044.2007.05055.x","article-title":"Propofol infusion syndrome","volume":"62","author":"Kam","year":"2007","journal-title":"Anaesthesia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(00)04064-2","article-title":"Impaired fatty acid oxidation in propofol infusion syndrome","volume":"357","author":"Wolf","year":"2001","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/ALN.0000000000000484","article-title":"Possible pathogenic mechanism of propofol infusion syndrome involves coenzyme q","volume":"122","author":"Vanlander","year":"2015","journal-title":"Anesthesiology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41390-022-01985-1","article-title":"Propofol toxicity in the developing mouse heart mitochondria","volume":"92","author":"Barajas","year":"2022","journal-title":"Pediatr. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/0883073816661458","article-title":"Propofol is mitochondrion-toxic and may unmask a mitochondrial disorder","volume":"31","author":"Finsterer","year":"2016","journal-title":"J. Child. Neurol."},{"key":"ref_51","first-page":"79","article-title":"The propofol infusion \u2018syndrome\u2019 in intensive care unit: From pathophysiology to prophylaxis and treatment","volume":"59","author":"Papaioannou","year":"2008","journal-title":"Acta Anaesthesiol. Belg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1399-6576.2011.02628.x","article-title":"Inborn oxidative phosphorylation defect as risk factor for propofol infusion syndrome","volume":"56","author":"Vanlander","year":"2012","journal-title":"Acta Anaesthesiol. Scand."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bja.2024.05.018","article-title":"Propofol infusion syndrome (PRIS) incidence and related symptoms in children: A retrospective analysis of a nationwide hospital-based database in japan","volume":"133","author":"Takeshita","year":"2024","journal-title":"Br. J. Anaesth."},{"key":"ref_54","first-page":"e59948","article-title":"Safety of extended propofol infusions in critically ill pediatric patients","volume":"16","author":"Moas","year":"2024","journal-title":"Cureus"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40263-015-0259-6","article-title":"Propofol: A review of its role in pediatric anesthesia and sedation","volume":"29","author":"Chidambaran","year":"2015","journal-title":"CNS Drugs"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/4\/579\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T04:16:26Z","timestamp":1777090586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/4\/579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["children13040579"],"URL":"https:\/\/doi.org\/10.3390\/children13040579","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]}}}